Phase 2Not yet recruitingPriority 3 · Moderate priorityNCT07347288
SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
Plain-language summary
This Phase 2 trial is evaluating SHR2554 Tablets as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
SHR2554 Tablets (DRUG): SHR2554 orally twice daily
- Drugs / treatments
- SHR2554 Tablets
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details